| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802985301022 | 298530102 | SEROTIAPIN F.C.TAB 25MG/TAB BTx60 (σε PVC/Aluminium Blister) (σε PVC/Aluminium Blister) | 7.26 | 7.62 | 10.50 |
| 05/2018 | 2802985302029 | 298530202 | SEROTIAPIN F.C.TAB 100MG/TAB BTx60 (σε PVC/Aluminium Blister) (σε PVC/Aluminium Blister) | 13.75 | 14.42 | 19.88 |
| 05/2018 | 2802985303026 | 298530302 | SEROTIAPIN F.C.TAB 200MG/TAB BTx60 (σε PVC/Aluminium Blister) (σε PVC/Aluminium Blister) | 22.65 | 23.76 | 32.74 |
| 05/2018 | 2802985304023 | 298530402 | SEROTIAPIN F.C.TAB 300MG/TAB BTx60 (σε PVC/Aluminium Blister) (σε PVC/Aluminium Blister) | 31.31 | 32.84 | 45.25 |
| 05/2018 | 2803133401021 | 313340102 | SEROTIAPIN XR® PR.TAB 50MG/TAB ΒΤx30 tabs σε PVC/PVDC-Alu blisters | 3.32 | 3.48 | 4.79 |
| 05/2018 | 2803133401045 | 313340104 | SEROTIAPIN XR® PR.TAB 50MG/TAB ΒΤx60 tabs σε PVC/PVDC-Alu blisters | 4.76 | 4.99 | 6.88 |
| 05/2018 | 2803133402028 | 313340202 | SEROTIAPIN XR® PR.TAB 150MG/TAB ΒΤx30 tabs σε PVC/PVDC-Alu blisters | 11.33 | 11.88 | 16.37 |
| 05/2018 | 2803133402042 | 313340204 | SEROTIAPIN XR® PR.TAB 150MG/TAB ΒΤx60 tabs σε PVC/PVDC-Alu blisters | 18.04 | 18.92 | 26.08 |
| 05/2018 | 2803133403025 | 313340302 | SEROTIAPIN XR® PR.TAB 200MG/TAB ΒΤx30 tabs σε PVC/PVDC-Alu blisters | 7.76 | 8.14 | 11.21 |
| 05/2018 | 2803133403049 | 313340304 | SEROTIAPIN XR® PR.TAB 200MG/TAB ΒΤx60 tabs σε PVC/PVDC-Alu blisters | 15.18 | 15.92 | 21.94 |
| 05/2018 | 2803133404022 | 313340402 | SEROTIAPIN XR® PR.TAB 300MG/TAB ΒΤx30 tabs σε PVC/PVDC-Alu blisters | 14.52 | 15.23 | 20.99 |
| 05/2018 | 2803133404046 | 313340404 | SEROTIAPIN XR® PR.TAB 300MG/TAB ΒΤx60 tabs σε PVC/PVDC-Alu blisters | 25.55 | 26.80 | 36.93 |
| 05/2018 | 2803133405029 | 313340502 | SEROTIAPIN XR® PR.TAB 400MG/TAB ΒΤx30 tabs σε PVC/PVDC-Alu blisters | 24.60 | 25.81 | 35.56 |
| 05/2018 | 2803133405043 | 313340504 | SEROTIAPIN XR® PR.TAB 400MG/TAB ΒΤx60 tabs σε PVC/PVDC-Alu blisters | 43.31 | 45.43 | 62.60 |
For the treatment of schizophrenia and related psychotic disorders.
Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.
Rapidly and well absorbed.
6 hours
Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.
* 10±4 L/kg